September 9, 2022 – EmsanaRx, a public benefit corporation, and Cleveland Clinic have announced a first-of-its-kind strategic affiliation today. This collaboration will align EmsanaRx with Cleveland Clinic to further both organizations’ mission of providing cost-effective, high-quality care.
Cleveland Clinic will advise clinicians and multidisciplinary teams at EmsanaRx to support the company’s formulary development and utilization management programs and inform some of its benefit offerings. The health system will provide outside perspective on the clinical value of new and existing medications, treatments and therapies, based on its best practices for patient care and expertise in the latest technologies and innovations in healthcare.
This strategic affiliation creates opportunities to provide new treatments to patients, lower prescription drug costs, and expand clinical programs. Its goals include delivering reliable information, and improving quality and patient satisfaction to EmsanaRx’s large employer clients and the lives they serve. EmsanaRx will ensure members’ needs are met and drive clinical decision making.
“Through this collaboration, we can improve how effectively we serve our large employer clients. Management of pharmacy benefits is complex. EmsanaRx provides a better member experience with less disruption and we can advance the industry to benefit our communities by working together on programs like this,” said Greg Baker, co-founder and CEO of EmsanaRx. “This agreement allows us to remain true to our mission and vision by bringing a world class clinical expertise to drive superior outcomes.”
As the only pharmacy benefit manager (PBM) built by employers, EmsanaRx’s mission is to bring clarity, integrity and trust to pharmacy benefit management. EmsanaRx is committed to delivering a clinically focused, transparent and easy-to-use pharmacy benefit experience to its members.